Company
Headquarters: Yilan City, Taiwan
CEO: Mr. Zhiwen Li
TW$5.58 Billion
TWD as of Jan. 1, 2025
US$170.0 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $113.24 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $76.33 B |
Marinomed Biotech AG | $56.13 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. It produces anti-cancer pharmaceuticals, such as injections, solid reagents, and hormone reagents; and tablets, soft gel capsules and powder and canned special nutrient products. The company also provides shampoo, body wash, tonic water, lotions, moisturizers, sunscreen lotions, and serums; and pharmaceutical packaging products, such as eye drop bottles, dry canisters, tablet bottles, and various medical grade plastic containers. In addition, it offers plant extracts and functional foods; and OEM services, such as product design, manufacturing, etc. to manufacturers. Sinphar Pharmaceutical Co.,Ltd. was founded in 1977 and is headquartered in Yilan City, Taiwan.
Sinphar Pharmaceutical Co.,Ltd. has the following listings and related stock indices.
Stock: TWSE: 1734 wb_incandescent